Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Unlikely To Act Unilaterally To Increase ClinicalTrials.gov Postings

Executive Summary

FDA believes it has the authority to independently post clinical study information on ClinicalTrials.gov, but does not plan to create a systematic process for increasing the number of industry-sponsored trials listed on the site

You may also be interested in...



FDA Delays ClinicalTrials.gov Report To Include Additional Oncology Studies

FDA will include three additional months of oncology study listings in its report on the ClinicalTrials.gov registry

FDA Delays ClinicalTrials.gov Report To Include Additional Oncology Studies

FDA will include three additional months of oncology study listings in its report on the ClinicalTrials.gov registry

ClinicalTrials.gov Compliance Will Improve, PhRMA Tells Rep. Waxman

Industry may need several years to come into complete compliance with ClinicalTrials.gov, the Pharmaceutical Research & Manufacturers of America indicated in a letter to Rep. Henry Waxman (D-Calif.)

Related Content

Topics

UsernamePublicRestriction

Register

PS044318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel